Evaluation of the potential for QTc prolongation with avelumab
- PMID: 31478078
- PMCID: PMC6795609
- DOI: 10.1007/s00280-019-03925-z
Evaluation of the potential for QTc prolongation with avelumab
Abstract
Purpose: To report integrated electrocardiogram (ECG) summary and exposure-QTc analyses for avelumab, a human immunoglobulin G1 monoclonal antibody that binds programmed cell death 1 ligand 1, to assess potential effects on cardiac repolarization.
Methods: Data were pooled from three-phase 1/2 studies of patients with advanced solid tumors who received avelumab monotherapy (22,000 ECGs from 1818 patients). All analyses used 12-lead singlet ECGs taken using local ECG machines before and approximately 2 h after avelumab infusion on prespecified days. The exposure-QTc and outlier analyses used locally read ECGs; since larger variability is known to be associated with local reading, outlier ECGs were subsequently reevaluated by central read. QTc derived from Fridericia's formula (QTcF) and a project-specific formula (QTcP) were analyzed. Multivariable linear mixed-effects models were used to describe the relationship between serum concentration of avelumab and QTc absolute value or change from baseline (ΔQTc).
Results: Exposure-QTc models showed that the effect of avelumab on QTc or ΔQTc was minimal and not statistically significant for both QTcP and QTcF. In addition, models including avelumab concentration and diphenhydramine premedication use did not show a clinically meaningful effect on the QT interval. The frequency of QTc outliers in both short and long ranges was overestimated by local reads. Six patients (0.3%) were QTc outliers; all had either received concomitant medication known to cause QT prolongation or had a preexisting cardiac condition.
Conclusion: Avelumab does not have any clinically relevant effect on cardiac repolarization.
Keywords: Avelumab; Cancer; PD-L1; QT interval; QTc; Solid tumor.
Conflict of interest statement
Y. Vugmeyster declares employment and patents with EMD Serono; H. Dai and M. Hennessy declare employment with EMD Serono; G. Güzel declares employment with Merck KGaA; A.H. Loos declares employment, patents, royalties, stock in, or other intellectual property with Merck KGaA.
Figures

Similar articles
-
Evaluation of the potential for QTc prolongation in patients with solid tumors receiving nivolumab.Cancer Chemother Pharmacol. 2016 Mar;77(3):635-41. doi: 10.1007/s00280-016-2980-3. Epub 2016 Feb 10. Cancer Chemother Pharmacol. 2016. PMID: 26861469 Clinical Trial.
-
Evaluation of the effect of necitumumab on the corrected QT interval in patients with advanced solid tumors.Cancer Chemother Pharmacol. 2016 Aug;78(2):271-80. doi: 10.1007/s00280-016-3074-y. Epub 2016 Jun 16. Cancer Chemother Pharmacol. 2016. PMID: 27312733 Clinical Trial.
-
Evaluation of the effect of the EGFR antibody-drug conjugate ABT-414 on QT interval prolongation in patients with advanced solid tumors likely to over-express EGFR.Cancer Chemother Pharmacol. 2017 May;79(5):915-922. doi: 10.1007/s00280-017-3284-y. Epub 2017 Mar 27. Cancer Chemother Pharmacol. 2017. PMID: 28349167 Clinical Trial.
-
Outcomes of screening Parkinson's patients for QTc prolongation.Parkinsonism Relat Disord. 2013 Nov;19(11):1000-3. doi: 10.1016/j.parkreldis.2013.07.001. Epub 2013 Jul 17. Parkinsonism Relat Disord. 2013. PMID: 23871463 Review.
-
Ciprofloxacin does not Prolong the QTc Interval: A Clinical Study in ICU Patients and Review of the Literature.J Pharm Pharm Sci. 2017;20(1):360-364. doi: 10.18433/J3ZD15. J Pharm Pharm Sci. 2017. PMID: 29145929 Review.
Cited by
-
Prediction of Cardiac Arrhythmias in Cancer Patients Treated with Immune Checkpoint Inhibitors Using Electrocardiogram.Diagnostics (Basel). 2025 May 14;15(10):1235. doi: 10.3390/diagnostics15101235. Diagnostics (Basel). 2025. PMID: 40428227 Free PMC article.
-
Left Ventricular Ejection Fraction in Patients With Ovarian Cancer Treated With Avelumab, Pegylated Liposomal Doxorubicin, or Both.Oncologist. 2023 Oct 3;28(10):e977-e980. doi: 10.1093/oncolo/oyad213. Oncologist. 2023. PMID: 37665777 Free PMC article. Clinical Trial.
-
Concentration-QTc analysis for single arm studies.J Pharmacokinet Pharmacodyn. 2021 Apr;48(2):203-211. doi: 10.1007/s10928-021-09737-0. Epub 2021 Jan 29. J Pharmacokinet Pharmacodyn. 2021. PMID: 33512637
References
-
- Bavencio (avelumab) (2019) [package insert]. Rockland, MA: EMD Serono
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials